RecruitingPhase 4NCT03671967

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial

Sponsor

Rambam Health Care Campus

Enrollment

1,084 participants

Start Date

May 1, 2019

Study Type

INTERVENTIONAL

Conditions

Enterobacteriaceae Infections Bacteremia Beta Lactam Resistant Bacterial Infection

Summary

Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Meropenem and a drug called Piperacillin/tazobactam for people with bacteremia, beta lactam resistant bacterial infection, and other related conditions. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPiperacillin/tazobactam

4.5 grams QID

DRUGMeropenem

1 gram TID

Locations(14)

University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health

Calgary, Alberta, Canada

Surrey Memorial Hospital - Fraser Health Authority

Surrey, British Columbia, Canada

Eastern Health

St. John's, Newfoundland and Labrador, Canada

Kingston General Hospital

Kingston, Ontario, Canada

Jewish Genral Hospital

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Rambam Health Care Campus

Haifa, Israel, Israel

Soroka Medical Center

Beersheba, Israel

Hadassah Medical Center

Jerusalem, Israel

Meir Medical Center

Kfar Saba, Israel

Sanz Medical Center-Laniado Hospital

Netanya, Israel

Rabin Medical Center, Beilinson Campus

Petah Tikva, Israel

Sheba Medical Center (Tel HaShomer)

Tel Aviv, Israel

Sourasky Medical Center

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03671967

Related Trials

Reducing Risk for Infective Endocarditis

NCT057217816 locations

Surveillance of AMR in DRC

NCT068212821 location

Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)

NCT057706224 locations

Febrile Infants Swedish Study

NCT0713475111 locations

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

NCT074863621 location